Nanomedical Devices Market Research Report- Forecast till 2030

Nanomedical Devices Market Research Report: By Type (Implantable Biosensors, Implantable Cardioverter-Defibrillators and others), Application (Disease Treatment and Diagnosis, Drug Release Regulation and others) by End User (Hospitals and Clinics, Research Institutes and Organizations and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa)- Forecast till 2030

ID: MRFR/MED/0728-HCR | January 2023 | Region: Global | 90 Pages         

Nanomedical Devices Market Speak to Analyst Request a Free Sample

Nanomedical Devices Market Scenario


The Nanomedical Devices Market is expected to reach USD 12,573.6 Million by 2030 at 14.8% CAGR during the forecast period 2022-2030


Nanomedical devices are the modern version of the devices used for the treatment and diagnosis of diseases. Since the last decade, there has been steep growth in the development of nanomedical devices. These devices are particularly used in in vivo testing and imaging. Around 250 nanomedical products are being tested or used on humans.


Segmentation


The Global Nanomedical Devices Market has been segmented based on type, application, and end user. Based on type, the market has been segmented into implantable biosensors, implantable cardioverter-defibrillators, and others. The implantable biosensors sub-segment is expected to be the largest type market as it has an ability to provide continuous data on the levels of a target analyte. Besides, it has great potential in the diagnosis, monitoring, management, and treatment of a variety of disease conditions, which would drive the growth of the nanomedical devices market.


The market, by application, has been classified as disease treatment and diagnosis, drug release regulation, and others. Disease treatment and diagnosis segment has been further bifurcated into cancer, neurological disease, cardiovascular disease, and others. Among this, the disease treatment and diagnosis sub-segment is the fastest growing in terms of value due to rising geriatric population, increasing prevalence of various diseases such as cancer, cardiovascular disease, among others, and is predicted to achieve more revenue in the upcoming nanomedical devices market.   


The market, based on end user, has been bifurcated into hospitals & clinics, research institutes and organizations, and others. Out of these, hospitals & clinics segment is the fastest-growing segment and is anticipated to hold a major market share in the market.


The market has been divided by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanomedical devices market in the Americas has further been branched into North America and Latin America. Within North American, market has been divided into the US and Canada. The European nanomedical devices market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, Italy, Spain, UK, and the rest of Western Europe. The nanomedical devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia. The market in the Middle East & Africa has been divided into the Middle East & Africa.


Key Players


The Key Players in Global Nanomedical Devices are 



  • Sanofi

  • Pfizer Inc

  • Celgene Corporation.

  • Luminex Corporation

  • Taiwan Liposome Company Ltd

  • Merck & Co. Inc.

  • Nanobiotix

  • Starpharma Holdings Limited

  • CYTIMMUNE SCIENCES INC.


   Regional Market Summary


Global Nanomedical Devices Market Share (%), by Region, 2018  


Nanomedical Devices Market


Source: World Health Organization (WHO), Institute of Medicine (IOM)


The market in America is projected to have a steady growth rate during the forecast period owing to the presence of technologically advanced healthcare infrastructure, an increase in patient and healthcare practitioner’s awareness levels relating to the advantages of nanomedical devices; this drives the growth of nanomedical devices market in this region.


The market in Europe showed a substantial amount of growth. The market growth in this region can be attributed to the favorable government policies, a rise in healthcare expenditure, and increasing technological advancements; these drive the growth of nanomedical devices market in this region.


The market in Asia-Pacific is expected to dominate the global nanomedical devices due to the rapid economic development and increasing geriatric population. For instance, according to the United Nations Population Fund, the population of older persons of age over 60 in this region will be triple between 2010 and 2050, reaching close to 1.3 billion people who would drive the growth of the nano medical devices market


The market in the Middle East and Africa is expected to grow at a substantial rate due to the increase in the prevalence of various diseases such as cardiovascular disease in this region.


Global Nanomedical Devices Market, by Type



  • Implantable biosensors

  • Implantable cardioverter-defibrillators

  • Others


Global Nanomedical Devices Market by Product Type




  • Disease Treatment and Diagnosis

    • Cancer

    • Neurological diseases

    • Cardiovascular diseases

    • Others



  • Drug Release Regulation

  • Others


Global Nanomedical Devices Market, by End User



  • Hospital & Clinics

  • Research Institutes and Organizations

  • Others


Global Nanomedical Devices Market, by Region




  • Americas

    • North America

    • US

    • Canada






  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe






  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific






  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Medical Device Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities

  • Venture Capitalists



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 12,573.6 Million
  CAGR   14.8% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Application, by End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi, Pfizer Inc, Celgene Corporation., Luminex Corporation, Taiwan Liposome Company, Ltd, Merck & Co., Inc., Nanobiotix, Starpharma Holdings Limited, CYTIMMUNE SCIENCES, INC
  Key Market Opportunities

  • The disease treatment and diagnosis sub-segment is the fastest growing in terms of value due to rising geriatric population\r\n
  • Increasing prevalence of various diseases such as cancer
  •   Key Market Drivers   Increasing use of surgical staples instead of needles and suture can deter the demand for cardiovascular needles


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The global nanomedical devices market had reached to a valuation of USD 12,573.6 Million in 2030.

    The global nanomedical devices market is estimated to grow at 14.8% CAGR during the forecast period (2022-2030).

    North America holds the largest share in the global nanomedical devices market followed by Europe and Asia Pacific, respectively.

    EnvisionTEC (USA), 3M Company (USA), EOS GmbH (Germany), PerkinElmer, Inc. (the USA), Medtronic (USA), Smith & Nephew PLC (UK), Starkey Hearing Technologies (USA), St. Jude Medical, Inc. (the USA), and Stryker Corporation (USA), are some of the major players operating in the global nanomedical devices market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global nanomedical devices market adopt to gain a larger competitive advantage.